These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 25934889)

  • 1. IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in Melanoma.
    Carson CC; Moschos SJ; Edmiston SN; Darr DB; Nikolaishvili-Feinberg N; Groben PA; Zhou X; Kuan PF; Pandey S; Chan KT; Jordan JL; Hao H; Frank JS; Hopkinson DA; Gibbs DC; Alldredge VD; Parrish E; Hanna SC; Berkowitz P; Rubenstein DS; Miller CR; Bear JE; Ollila DW; Sharpless NE; Conway K; Thomas NE
    Clin Cancer Res; 2015 May; 21(9):2167-76. PubMed ID: 25934889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomewide RNAi screen identifies protein kinase Cb and new members of mitogen-activated protein kinase pathway as regulators of melanoma cell growth and metastasis.
    Schönherr M; Bhattacharya A; Kottek T; Szymczak S; Köberle M; Wickenhauser C; Siebolts U; Saalbach A; Koczan D; Magin TM; Simon JC; Kunz M
    Pigment Cell Melanoma Res; 2014 May; 27(3):418-30. PubMed ID: 24406113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-derived tumor xenograft model to guide the use of BRAF inhibitors in metastatic melanoma.
    Guerreschi P; Scalbert C; Qassemyar A; Kluza J; Ravasi L; Huglo D; Martinot-Duquennoy V; Formstecher P; Marchetti P; Mortier L
    Melanoma Res; 2013 Oct; 23(5):373-80. PubMed ID: 23852164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of expression of protein kinase a regulatory subunit 1alpha in pigmented epithelioid melanocytoma but not in melanoma or other melanocytic lesions.
    Zembowicz A; Knoepp SM; Bei T; Stergiopoulos S; Eng C; Mihm MC; Stratakis CA
    Am J Surg Pathol; 2007 Nov; 31(11):1764-75. PubMed ID: 18059235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein kinase C inhibitor Gö6976 but not Gö6983 induces the reversion of E- to N-cadherin switch and metastatic phenotype in melanoma: identification of the role of protein kinase D1.
    Merzoug-Larabi M; Spasojevic C; Eymard M; Hugonin C; Auclair C; Karam M
    BMC Cancer; 2017 Jan; 17(1):12. PubMed ID: 28056869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases.
    Birner P; Berghoff AS; Dinhof C; Pirker C; Capper D; Schoppmann SF; Petzelbauer P; von Deimling A; Berger W; Preusser M
    Arch Dermatol Res; 2014 Dec; 306(10):873-84. PubMed ID: 25073704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphoinositide 3-kinase is not overexpressed in melanocytic lesions.
    Singh RS; Diwan AH; Zhang PS; Prieto VG
    J Cutan Pathol; 2007 Mar; 34(3):220-5. PubMed ID: 17302605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
    Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
    Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the IL-2-inducible tyrosine kinase (Itk) activity: a new concept for the therapy of inflammatory skin diseases.
    von Bonin A; Rausch A; Mengel A; Hitchcock M; Krüger M; von Ahsen O; Merz C; Röse L; Stock C; Martin SF; Leder G; Döcke WD; Asadullah K; Zügel U
    Exp Dermatol; 2011 Jan; 20(1):41-7. PubMed ID: 21158938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
    Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN
    J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression.
    Mudaliar K; Tetzlaff MT; Duvic M; Ciurea A; Hymes S; Milton DR; Tsai KY; Prieto VG; Torres-Cabala CA; Curry JL
    Hum Pathol; 2016 Apr; 50():79-89. PubMed ID: 26997441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models.
    Yang H; Higgins B; Kolinsky K; Packman K; Go Z; Iyer R; Kolis S; Zhao S; Lee R; Grippo JF; Schostack K; Simcox ME; Heimbrook D; Bollag G; Su F
    Cancer Res; 2010 Jul; 70(13):5518-27. PubMed ID: 20551065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ErbB receptor tyrosine kinases contribute to proliferation of malignant melanoma cells: inhibition by gefitinib (ZD1839).
    Djerf EA; Trinks C; Abdiu A; Thunell LK; Hallbeck AL; Walz TM
    Melanoma Res; 2009 Jun; 19(3):156-66. PubMed ID: 19434003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VS-5584, a Novel PI3K-mTOR Dual Inhibitor, Inhibits Melanoma Cell Growth In Vitro and In Vivo.
    Shao Z; Bao Q; Jiang F; Qian H; Fang Q; Hu X
    PLoS One; 2015; 10(7):e0132655. PubMed ID: 26204252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel.
    Haass NK; Sproesser K; Nguyen TK; Contractor R; Medina CA; Nathanson KL; Herlyn M; Smalley KS
    Clin Cancer Res; 2008 Jan; 14(1):230-9. PubMed ID: 18172275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets.
    Scortegagna M; Lau E; Zhang T; Feng Y; Sereduk C; Yin H; De SK; Meeth K; Platt JT; Langdon CG; Halaban R; Pellecchia M; Davies MA; Brown K; Stern DF; Bosenberg M; Ronai ZA
    Cancer Res; 2015 Apr; 75(7):1399-412. PubMed ID: 25712345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.
    Ramsdale R; Jorissen RN; Li FZ; Al-Obaidi S; Ward T; Sheppard KE; Bukczynska PE; Young RJ; Boyle SE; Shackleton M; Bollag G; Long GV; Tulchinsky E; Rizos H; Pearson RB; McArthur GA; Dhillon AS; Ferrao PT
    Sci Signal; 2015 Aug; 8(390):ra82. PubMed ID: 26286024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The retinoid derivant ECPIRM selectively exhibited anti-proliferation effects in cutaneous T-Cell lymphoma via ITK-mediated signaling pathway.
    Li H; Wang C; Ma P; Zhang M; Yang H; Yuan S; Wei J; Tao L; Qian K; Xu M; Li L
    J Dermatol Sci; 2020 Mar; 97(3):208-215. PubMed ID: 32165081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RT-PCR-based tyrosine kinase display profiling of canine melanoma: IGF-1 receptor as a potential therapeutic target.
    Thamm DH; Huelsmeyer MK; Mitzey AM; Qurollo B; Rose BJ; Kurzman ID
    Melanoma Res; 2010 Feb; 20(1):35-42. PubMed ID: 19949352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell differentiation and cell-cycle alterations by tyrosine kinase inhibitors in human melanoma cells.
    Hartmann RR; Rimoldi D; Lejeune FJ; Carrel S
    Melanoma Res; 1997 Aug; 7 Suppl 2():S27-33. PubMed ID: 9578414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.